Nidhi Agrawal
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1700208915
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Chiesi USA, Inc. at 46.4% of the total. Reporting peaked in 2024 at $13,455 and has fallen 61.8% since, to $5,138 in 2025.
Across 34 payments — averaging $852.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$13K
- Amryt Pharma Holdings Ltd$8K
- Novo Nordisk$5K
- Chiasma, Inc.$2K
- Abbott$155
- Boston Scientific$123
- plus $260 from 4 others
Across 90 payments — averaging $3024.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$182K
- Novo Nordisk AS$33K
- Recordati_rare_diseases_inc.$26K
- Chiasma, Inc.$20K
- Amryt Pharma Holdings Ltd$11K
- Chiesi USA, Inc.$925
What the payments were for
- Consulting fees$13,50847%
- Speaking & faculty fees$9,73034%
- Travel & lodging$4,56016%
- Food & beverage$1,1294%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 11 | $13,455 |
| Amryt Pharma Holdings Ltd | 5 | $7,996 |
| Novo Nordisk | 6 | $5,187 |
| Chiasma, Inc. | 1 | $1,800 |
| Abbott | 2 | $155 |
| Boston Scientific | 5 | $123 |
| Merck | 1 | $113 |
| Pfizer | 1 | $76 |
| Ipsen Biopharmaceuticals, Inc | 1 | $50 |
| Boehringer Ingelheim | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,976 in reported general payments places this provider in the 85th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Somatuline DepotLanreotide Acetate | 19 | $159,745 |
| IsturisaOsilodrostat Phosphate | 18 | $60,820 |
| XyostedTestosterone Enanthate | 19 | $14,305 |
| Testosterone | 23 | $4,220 |
| Hydrocortisone | 71 | $3,419 |
| TirosintLevothyroxine Sodium | 14 | $2,920 |
| Levothyroxine Sodium | 127 | $2,324 |
| SynthroidLevothyroxine Sodium | 23 | $2,118 |
| Cabergoline | 33 | $1,515 |
| Metformin Hcl ErMetformin Hcl | 23 | $309 |
| Omega-3 Acid Ethyl Esters | 13 | $120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $50 | $159,74519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New York
- John BilezikianNew York$809K
- Anastasios ManessisNew York$656K
- Jason BakerNew York$427K
- Brian LevyNew York$417K
- Stuart WeissNew York$275K
- Priya JaisinghaniNew York$239K
- Henry GinsbergNew York$161K
- Recaredo BerbanoNew York$146K
- Beverly TchangNew York$120K
- Shira EytanNew York$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.